低危或中低危复发风险甲状腺乳头状癌的选择性放射性碘治疗
该回顾性研究在学术转诊中心纳入非侵袭性甲状腺乳头状癌患者,比较常规全甲状腺切除加放射性碘治疗与术后约12个月再决定是否行放射性碘治疗两个时期的实践。结果显示选择性使用放射性碘使早期随访中「不确定」状态增多,但结构不完全缓解率始终较低(1%-3%),两队列各随访时点无差异。
要点
- 选择性使用放射性碘可减少治疗暴露,但早期随访「灰区」反应增多。
- 无论是否即刻使用放射性碘,结构不完全缓解率均低(1%-3%)。
- 应告知患者省略放射性碘治疗的获益与不足。
核心结论
- 选择性使用放射性碘增加早期随访中「不确定」状态的患者比例,但结构不完全缓解率仍然较低,与是否即刻使用放射性碘无关。
研究设计与样本
- 学术转诊中心非侵袭性甲状腺乳头状癌患者的回顾性纵向数据分析;队列1(2005年5月至2011年6月)接受全甲状腺切除加放射性碘治疗,队列2(2011年7月至2018年12月)术后约12个月再决定是否行放射性碘治疗;采用倾向评分匹配调整性别、年龄、肿瘤大小、淋巴结状态和甲状腺外侵犯。
主要发现
- 队列1中116例患者有50例(51.7%)接受放射性碘治疗;队列2中156例仅10例(6.4%)即刻接受,另有3例在首次随访数据后接受。
- 结构不完全缓解频率低(1%-3%),两队列在任何随访访视中均无差异。
- 队列2患者「灰区反应」(生化不完全或不确定反应)发生率更高。
临床怎么用
- 对非侵袭性、无远处转移且中央区淋巴结转移≤5个的甲状腺乳头状癌患者,可考虑术后约12个月再决定是否行放射性碘治疗。
- 向患者说明省略放射性碘治疗的优势与不足,并在早期随访中预期「不确定」状态可能增多。
局限性
- 为单中心回顾性纵向分析,结果可能受中心实践与患者选择影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Current guidelines recommend a selective use of radioiodine treatment (RAI) for papillary thyroid cancer (PTC). OBJECTIVE: This work aimed to determine how policy changes affect the use of RAI and the short-term outcomes of patients. METHODS: A retrospective analysis of longitudinal data was conducted in an academic referral center of patients with nonaggressive PTC variants; no extrathyroidal invasion or limited to soft tissues, no distant metastases, and 5 or fewer central-compartment cervical lymph node metastases. In cohort 1, standard treatments were total thyroidectomy and RAI (May 2005-June 2011); in cohort 2 decisions on RAI were deferred for approximately 12 months after surgery (July 2011-December 2018). Propensity score matching was used to adjust for sex, age, tumor size, lymph node status, and extrathyroidal extension. Intervention included immediate RAI or deferred choice. Main outcome measures were responses to initial treatment during 3 or more years of follow-up. RESULTS: In cohort 1, RAI was performed in 50 of 116 patients (51.7%), whereas in cohort 2, it was far less frequent: immediately in 10 of 156 (6.4%), and in 3 more patients after the first follow-up data. The frequencies of structural incomplete response were low (1%-3%), and there were no differences between the 2 cohorts at any follow-up visit. Cohort 2 patients had higher rates of "gray-zone responses" (biochemical incomplete or indeterminate response). CONCLUSION: Selective use of RAI increases the rate of patients with "uncertain" status during early follow-up. The rate of structural incomplete responses remains low regardless of whether RAI is used immediately. Patients should be made aware of the advantages and drawbacks of omitting RAI.
引用
- Grani G, Lamartina L, Alfò M, et al. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk. J Clin Endocrinol Metab. 2021. PMID: 33377969. doi:10.1210/clinem/dgaa973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。